nach oben

Current Atherosclerosis Reports

Erschienen in:

01.09.2021 | Reviews and New Research Implications (S. Virani, Section Editor)

Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention

verfasst von: Vardhmaan Jain, Mahmoud Al Rifai, Dhruv Mahtta, Jing Liu, Aliza Hussain, Salim S. Virani

Erschienen in: Current Atherosclerosis Reports | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review highlights late-breaking science presented at the Virtual American College of Cardiology Scientific Sessions 2021 that demonstrated advancements in preventative cardiology and introduced novel therapeutic modalities for the management of chronic kidney disease, heart failure, and COVID-19.

Recent Findings

The studies reviewed include clinical trials that assessed the use of dapagliflozin in patients with respiratory failure due to COVID-19 (DARE-19 trial); evinacumab for patients with severe hypertriglyceridemia and pancreatitis; effect of genotype-guided oral P2y12 inhibitors vs conventional clopidogrel on long-term ischemic outcomes after percutaneous coronary intervention (TAILOR-PCI trial); anticoagulation in patients hospitalized with COVID-19 (ACTION trial); atorvastatin vs placebo in patients with COVID-19 admitted to the ICU (INSPIRATION-S trial); rehabilitation therapy in older acute heart failure patients (REHAB-HF trial); and aspirin dosing: a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE trial). In addition, we review the results of the American College of Cardiology Global Heart Attack Initiative (GHATI). Finally, we discuss the secondary analysis of the STRENGTH trial assessing the association of achieved levels of omega-3 fatty acid levels and major cardiovascular outcomes.

Summary

The studies presented at the virtual American College of Cardiology Scientific Session 2021 represent remarkable contributions in the field of cardiovascular disease and prevention.

Nissen SE, Lincoff AM, Wolski K, Ballantyne CM, Kastelein JJP, Ridker PM, Ray KK, McGuire DK, Mozaffarian D, Koenig W, Davidson MH, Garcia M, Katona BG, Himmelmann A, Loss LE, Poole M, Menon V, Nicholls SJ Association between achieved ω-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH trial. JAMA Cardiol. (2021) https://doi.org/10.1001/jamacardio.2021.1157

2.•

Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;2021. https://doi.org/10.1056/NEJMoa2102137In a randomized trial of over 15,000 participants with established coronary artery disease randomized to receive either aspirin 81mg or aspirin 325mg, there was no difference in the rate of adverse cardiac events or major bleeding. However, there was significant dose switching in the group assigned to receive aspirin 325 mg.

3.••

Kitzman DW, Whellan DJ, Duncan P, et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med. 2021;2021. https://doi.org/10.1056/NEJMoa2026141In 349 older patients who were hospitalized for acute decompensated heart failure randomized to either routine care or an early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains, there was a greater improvement in physical function in the group that received rehabilitation than usual care. While there was no difference in all-cause mortality or rate of readmission, the improvement in functional status was clinically meaningful.

Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324:761–71.CrossRef

Hussain A, Al Rifai M, Mahtta D, Liu J, Jain V, Virani SS. Highlights from studies presented at the American Heart Association Scientific Session 2020: navigating new roads in prevention. Curr Atheroscler Rep. 2020;23:1–9.

Jia X, Al Rifai M, Hussain A, Martin S, Agarwala A, Virani SS. Highlights from studies in cardiovascular disease prevention presented at the digital 2020 European Society of Cardiology Congress: prevention is alive and well. Curr Atheroscler Rep. 2020;22:72.CrossRef

Jia X, Al Rifai M, Liu J, Agarwala A, Gulati M, Virani SS. Highlights of Studies in cardiovascular disease prevention presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2020;22:32.CrossRef

8.••

Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–39 In a randomized trial of 10,584 heart failure patients with diabetes and chronic kidney disease, sotagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of cardiac death and hospitalizations/urgent care visits for heart failure.CrossRef

9.••

Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–28 In a randomized trial of 1,222 patients with diabetes who were hospitalized for worsening heart failure, sotagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of cardiac death and hospitalizations/urgent care visits for heart failure.CrossRef

10.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.CrossRef

11.

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.CrossRef

12.

Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction | NEJM. https://www.nejm.org/doi/full/10.1056/NEJMoa1908655. Accessed 22 May 2021, 2019

13.

Williams DM, Evans M. Dapagliflozin for heart failure with preserved ejection fraction: will the DELIVER study deliver? Diabetes Ther. 2020;11:2207–19.CrossRef

14.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial. Eur J Heart Fail. 2019;21:1279–87.CrossRef

15.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7.CrossRef

16.

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.CrossRef

17.

Jia X, Virani SS. Statins in COVID-19 infection: a rehash of old themes or truly a new hope? Journal of Clinical Lipidology. 2021;15:399–401. https://doi.org/10.1016/j.jacl.2021.04.002.CrossRefPubMedPubMedCentral

18.

Simvastatin in the acute respiratory distress syndrome | NEJM. https://www.nejm.org/doi/full/10.1056/nejmoa1403285. Accessed 22 May 2021, 2014

19.

Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691–8.CrossRef

20.

Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021;12:1325.CrossRef

21.

Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169:572–8.CrossRef

22.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8.CrossRef

23.

Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.CrossRef

24.

Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25:689–94.CrossRef

25.

Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69:2054–63.CrossRef

26.

Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211–21.CrossRef

27.

Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140:470–86.CrossRef

28.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.CrossRef

29.

Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. JAMA. 2020;324:2268–80.CrossRef

30.

Virani SS, Nambi V, Ballantyne CM. Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH. European Heart Journal - Cardiovascular Pharmacotherapy. 2021;7:e7–8.CrossRef

31.

Levenson B, Herrera C, Wilson BH. New ACC global heart attack treatment initiative: improving STEMI Care worldwide. J Am Coll Cardiol. 2020;75:1605–8.CrossRef

32.

Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–30.CrossRef

33.

Jones WS, Mulder H, Wruck LM, et al (2021) Comparative effectiveness of aspirin dosing in cardiovascular disease. New England Journal of Medicine 0:null

Titel: Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention
verfasst von: Vardhmaan Jain
Mahmoud Al Rifai
Dhruv Mahtta
Jing Liu
Aliza Hussain
Salim S. Virani
Publikationsdatum: 01.09.2021
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 9/2021
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-021-00952-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention